Berenberg Bank restated their hold rating on shares of Hikma Pharmaceuticals (LON:HIK – Free Report) in a research note released on Thursday, MarketBeat reports. They currently have a GBX 2,000 ($24.70) price target on the stock.
Separately, Barclays reiterated an equal weight rating and issued a GBX 2,000 ($24.70) price target on shares of Hikma Pharmaceuticals in a research note on Monday, April 8th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus price target of GBX 2,068.75 ($25.55).
Hikma Pharmaceuticals Trading Up 3.2 %
Hikma Pharmaceuticals Increases Dividend
The company also recently declared a dividend, which will be paid on Friday, May 3rd. Investors of record on Thursday, March 21st will be paid a dividend of $0.47 per share. This represents a yield of 1.86%. The ex-dividend date is Thursday, March 21st. This is an increase from Hikma Pharmaceuticals’s previous dividend of $0.25. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is currently 8,507.46%.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Further Reading
- Five stocks we like better than Hikma Pharmaceuticals
- High Dividend REITs: Are They an Ideal Way to Diversify?
- MarketBeat Week in Review – 4/22 – 4/26
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3 Stocks Leading the U.S. Agriculture Comeback
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.